Please assess the completion status of the following clinical trial:

Trial Title: Long-term Efficacy and Safety of Repeated Ofatumumab Treatment Courses in RA Patients Who Previously Received Ofatumumab or Placebo in Trial Hx-CD20-403

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Previously received ofatumumab or placebo in Trial Hx-CD20-403.~* Patients on methotrexate therapy (7.5 - 25 mg/week, p.o., i.m., and/or s.c.).~* Oral corticosteroids therapy (≤ 10 mg/day prednisolone or equivalent).~* Active disease at the time of screening as defined by:~  * 3 swollen joints (of 28 joints assessed) and ≥ 3 tender joints (of 28 joints assessed), DAS28≥3.2 (based on ESR)~Exclusion Criteria:~* Use of DMARDs other than methotrexate or exposure to other cell depleting therapy, including investigational compounds \< 6 months prior to Visit 2 A.~* Patients who have received treatment with any non-marketed drug substance within 4 weeks prior to Visit 1 (screening).~* Breast feeding women or women with a positive pregnancy test at Visit 1 (screening).~* Received anti-cancer therapy, corticosteroids (intra-articular, i.m., or i.v.), or live/attenuated vaccinations, or exposure to cyclophosphamide, nitrogen mustard, chlorambucil or other alkylating agents \< 5 years prior to screening.~* Past or current malignancy, except for Cervical carcinoma Stage 1B or less, Non-invasive basal cell and squamous cell skin carcinoma, Malignant melanoma with a complete response of a duration of \> 10 years, or other cancer diagnoses with a complete response of a duration of \> 5 years.~* Chronic or ongoing active infectious disease requiring systemic treatment.~* Clinically significant cardiac disease, or history of significant cerebrovascular disease.~Significant concurrent, uncontrolled medical conditions, but not limited to, renal, hepatic, hematological, gastrointestinal, endocrine, pulmonary, neurological, cerebral psychiatric disease~* Known or suspected HIV positive, positive serology for hepatitis B (HB), positive test for Hepatitis C, or positive plasma or white cell JC virus (JCV) PCR (either compartment).~* A circulating IgG level \<lower limit of normal.~* Known hypersensitivity to components of the investigational medicinal product.~* Patients known or suspected of not being able to comply with a study protocol.~* Women of child bearing potential not will to use adequate contraception during study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ofatumumab (Type: EXPERIMENTAL): 1000 mL dilution of 35mls ofatumumab in sterile, pyrogen free, 0.9% NaCl

Based on this trial design, predict the completion outcome and termination type (if applicable).